OSCR
Oscar Health, Inc. Health Care Hospital & Medical Service Plans Russell 3000
$30.37Close
$10.85 – $34.3252-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- Leading the market RS 92 · stronger than 92% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
down 2.0%
price change
1mo
down 1.5%
price change
12-month return
up 68%
market up 11% ·
its own up 50%
F-score
—
— Not assessed
Altman Z″
-2.19
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 39%
year on year
EPS growth
—
latest quarter
Sales growth
down 6%
latest quarter · -38 pts
ROE
down 45%
return on equity
Free cash margin
up 3702%
$1.1B FCF
D/E
0.44
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-4% then +39%)
Trade setup
ATR%
4.9%
$1.49 a day · 2×ATR $27.39
RS
92 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.7×
vs 50-day average
Up/down volume
1.12
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 6, 2026
Last shock
Aug 6, 2026-12% in one session2.6× volumeon results+14% since
Financials
- Net -1550%
- Free cash 3702%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $5.4M | $64.9M | $21.4M | $20.6M | $28.6M |
| Operating income | -$402.3M | -$544.5M | -$589.9M | -$235.6M | $57.3M | -$396.4M |
| Net income | -$406.8M | -$572.6M | -$606.3M | -$270.7M | $25.4M | -$443.2M |
| Net margin | — | -10616% | -934% | -1268% | 124% | -1550% |
| Earnings per share | -$13.90 | -$3.20 | -$2.85 | -$1.22 | $0.10 | -$1.69 |
| Free cash flow | $208.7M | -$207.6M | $351.3M | -$297.7M | $950.3M | $1.1B |
| Free cash margin | — | -3849% | 541% | -1394% | 4618% | 3702% |
| Cash | $826.3M | $1.1B | $1.6B | $1.9B | $1.5B | $2.8B |
| Long-term debt | $142.5M | $0 | $298.0M | $298.8M | $299.6M | $430.1M |
| Shareholders' equity | -$1.3B | $1.4B | $890.4M | $804.0M | $1.0B | $977.6M |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 13, 2026 | Annual ↗ | Dec 31, 2025 | 44d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 15, 2024 | Annual ↗ | Dec 31, 2023 | 46d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 16, 2026 | Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 9, 2026 | Shareholder vote ↗ |
| Jun 8, 2026 | Regulation FD ↗ |
| Jun 2, 2026 | Director or officer change ↗ |
| May 6, 2026 | Results ↗ |
| Apr 21, 2026 | Regulation FD ↗ |
| Mar 2, 2026 | Regulation FD ↗ |
| Feb 10, 2026 | Material agreement · Results · New obligation ↗ |
| Dec 29, 2025 | Director or officer change ↗ |
| Nov 6, 2025 | Results · Other events ↗ |
| Sep 18, 2025 | Material agreement · New obligation · Unregistered share sale ↗ |